Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| NEE-MY2069 | Mouse | Monoclonal Anti-Influenza A virus NA (H1N1) (Victoria/2570/2019) Antibody, Human IgG1 (8E5) (MALS verified) |
|
|
|
| NEE-V524x | Influenza A virus (A/Croatia/10136RV/2023) & (A/District of Columbia/27/2023) | Influenza A virus (A/Croatia/10136RV/2023) & (A/District of Columbia/27/2023) NA(H3N2) Protein, His Tag |
|
The purity of Monoclonal Anti-Influenza A virus NA (H1N1) (Victoria/2570/2019) Antibody, Human IgG1 (8E5) (Cat. No. NEE-MY2069) is more than 90% and the molecular weight of this protein is around 135-160 kDa verified by SEC-MALS.
Immobilized Influenza A [Victoria/2570/2019(H1N1)] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V524e) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Influenza A virus NA (H1N1) (Victoria/2570/2019) Antibody, Human IgG1 (8E5) (Cat. No. NEE-MY2069) with a linear range of 0.3-5 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Laninamivir Octanoate Hydrate | CS-8958; R-118958 | Approved | Daiichi Sankyo Co Ltd | Inavir | Japan | Influenza B virus infection; Influenza A virus infections; Influenza, Human | null | 2010-09-10 | Influenza A virus infections; Influenza, Human; Asthma; Influenza B virus infection | Details |
| Zanamivir | GG-167; GR-121167; GR-121167X; 4-Guanidino-Neu5Ac2en | Approved | Glaxosmithkline Plc | 依乐韦, Relenza | United States | Influenza, Human | Glaxosmithkline Plc | 1999-07-26 | Orthomyxoviridae Infections; Diabetes Mellitus, Type 2; Influenza, Human; Arthralgia; Dengue | Details |
| Oseltamivir Phosphate | Ro-64-0796; GS-4104; RO-640796; GS-4104-002; EN-241104; RO-640796/002; GS-4104/002 | Approved | F. Hoffmann-La Roche Ltd | Tamiflu, Hanmi Flu, 达菲 | Switzerland | Influenza, Human | F. Hoffmann-La Roche Ltd | 1999-09-21 | Purpura, Thrombocytopenic, Idiopathic; Influenza A virus infections; Influenza, Human; Influenza in Birds; Parturition; Obesity; Kidney Failure, Chronic | Details |
| Peramivir Hydrate | BCX-1812; JNJ-2; S-021812; RWJ-270201 | Approved | Biocryst Pharmaceuticals Inc | Peramiflu, Alpivab, 力纬, Rapiacta, Rapivab, Enpiflu Premix | Japan | Influenza, Human | null | 2010-01-13 | Headache; Cough; Myalgia; Fatigue; Influenza A virus infections; Influenza, Human; Fever; Nasal Obstruction; Pharyngitis; Influenza B virus infection | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Peramivir Inhalation Solution (广州南鑫药业) | Phase 2 Clinical | Guangzhou Nanxin Pharma Co Ltd | Cough; Headache; Musculoskeletal Pain; Fatigue; Influenza A virus infections; Influenza, Human; Arthralgia; Nasal Obstruction; Influenza B virus infection | Details | |
| HNC042 | HNC-042 | Phase 1 Clinical | Guangzhou Henovcom Bioscience Co Ltd | Influenza A virus infections; Influenza, Human; Influenza B virus infection | Details |
| Oseltamivir/Pimodivir | Phase 1 Clinical | Johnson & Johnson | Influenza A virus infections | Details | |
| Oseltamivir orally disintegrating tablets | HY-100209 | Phase 1 Clinical | Hefei Industrial Pharmaceutical Co Ltd | Influenza A virus infections; Influenza B virus infection | Details |
This web search service is supported by Google Inc.
A-Z
